ATOLTIVIMAB; ODESIVIMAB; MAFTIVIMAB | B761169 | REGENERON PHARMACEUTICALS
Regulatory Exclusivities
| Type | Expiry | Status | Source |
|---|---|---|---|
| 12-Year BPCIA | Oct. 14, 2032 | Active | Computed |
| 7-Year Orphan | Oct. 14, 2027 | Active | Purple Book |
Purple Book Patents
No listed patents in Purple Book.
Estimated Patent LOE
Based on latest discovered patent 12152067(composition) · relevance 95/100
Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.
Top 50 of 100 AI-discovered patents by relevance.
No patent or exclusivity listings for this strength.